<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333252</url>
  </required_header>
  <id_info>
    <org_study_id>1803019068</org_study_id>
    <secondary_id>5R01AG054009</secondary_id>
    <nct_id>NCT03333252</nct_id>
  </id_info>
  <brief_title>A Non-pharmacological Intervention for Patients With Alzheimer's Disease and Family Caregivers (Care Partners Program)</brief_title>
  <acronym>CPProgram</acronym>
  <official_title>Dual Target Program: An Non-pharmacological Intervention for Family Caregivers and Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will develop and test the efficacy and feasibility of a dyadic-based
      intervention program (DT), delivered through state-of-the art computer tablet technology. A
      novel feature of the investigation is its focus on both the caregiver and the recipient of
      care (person with AD) and the integration of an evidenced-based caregiver intervention and
      evidenced-based cognitive/functional training for the care recipient. The program will be
      tailored for the caregiver and emphasize issues important to caregivers, not only in the
      earlier stages of caregiving, but will also target issues across the caregiving trajectory to
      help prepare the caregiver for changes in their role. Two hundred and forty Hispanic, African
      American and White/Caucasian dyads will be randomized to the DT intervention or Control
      condition. Measures at baseline and the 6 and 12-month follow-ups will include indices of
      care recipient cognitive and functional status, and caregiver outcomes such as; quality of
      life, distress, and caregiving efficacy. Information will also be gathered on ethnic
      differences in response to the intervention and estimates of cost effectiveness of the
      intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will recruit and randomly assign, following a baseline assessment, 246 dyads will be
      enrolled and randomly assigned to one of two groups: 1) Caregiving Condition or 2) Health
      Promotion (Nutrition) Condition. The entire study is home-based. The intervention will be
      delivered over 6 months using computer tablet technology in Spanish or English. Assessments
      will occur in the beginning of the study, 6 months, and 12 months (after completion of the
      intervention)

      Interested participants (caregivers) can contact us via telephone or email after seeing a
      flyer posted in various WCM/NYP locations including the Irving Sherwood Wright Center on
      Aging. One of our research associates (RA) will provide more information about the study to
      potential participants. The trained RA will use a telephone script with consent language to
      obtain permission to ask them questions to determine their eligibility through a phone screen
      script. If the participant is ineligible for the study, all screening data will be deleted.
      If the caregiver participant is eligible for the study, an appointment will be provided, and
      one of our RAs will visit the participants (caregiver and care recipient) and conduct the
      baseline assessment at the participants' home in their preferred language (Spanish or
      English). This assessment with the caregiver will last between 2 and 3 hours, additionally
      the assessment with the care recipient will last approximately 1.5 hours. We will use
      Qualtrics (online survey/data collection service) to administer the assessments.

      The baseline assessment with the caregiver (CG) consists of a series of questionnaires
      assessing the help provided by the CG to the care recipient (e.g., ADLs/AIDLs), the level of
      burden, stress, and depression perceived by the CG while providing the care, the amount of
      social support available to the CG, and the preparedness of the CG to provide continuing care
      to their loved ones. The assessment with the care recipient consists of measures of
      depression, executive functioning (Trails A &amp; B), working memory (Letters and Number set),
      processing speed (digit symbol), and verbal fluency (category fluency). In addition, the care
      recipient will complete a computer-based suite of tasks (e.g., ATM, prescription refill,
      forms filling, etc) assessing their functional status. The assessment with the caregiver and
      care recipient might not be completed in the same home visit. The study protocol allows
      multiple visits to complete the assessments.

      During the baseline home visit, the RA will go over the written informed consent and HIPAA
      authorization with the participants (caregiver and care recipient). The assessment will not
      begin unless the participant has a full understanding of the informed consent form and has
      signed the form. The care recipient will additionally be given a Consent Feedback Tool, as an
      added step to make sure they understand the consent form since they have mild cognitive
      impairment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in depression score for caregiver as measured by CES-D</measure>
    <time_frame>Baseline, 6-mth follow-up and 12-mth follow-up</time_frame>
    <description>Higher score means greater frequency of depressive symptoms. Range (0-30)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in caregiving burden score for caregiver as measured by Burden Inventory</measure>
    <time_frame>Baseline, 6-mth follow-up and 12-mth follow-up</time_frame>
    <description>Higher score means greater level of caregiver burden. Range (0-44)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in caregiver's self report of Self-care</measure>
    <time_frame>Baseline, 6-mth follow-up and 12-mth follow-up</time_frame>
    <description>Higher score means better in keeping medical obligations to him/herself. Range (0-12)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in caregiver's Social Support</measure>
    <time_frame>Baseline, 6-mth follow-up and 12-mth follow-up</time_frame>
    <description>Higher score means more social support for the caregiver. Range (0-40)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in care recipient's Qualify of Life</measure>
    <time_frame>Baseline, 6-mth follow-up, and 12-mth follow-up</time_frame>
    <description>Higher score means better quality of life as Alzheimer's patient. Range (0-52)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in care recipient's processing speed using Digit Symbol test</measure>
    <time_frame>Baseline, 6-mth follow-up, and 12-mth follow-up</time_frame>
    <description>Higher score means faster processing speed. Range (0-100)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Caregiver</condition>
  <arm_group>
    <arm_group_label>Intervention Condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exposing caregivers to caregiving-related information and care recipients to cognitive training tasks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Condition</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Exposing caregivers to Nutrition and Health promotional material. The care recipients are exposed to plain words games from computer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intervention Condition</intervention_name>
    <description>Caregivers will access caregiving related information. Care Recipients will access cognitive training program</description>
    <arm_group_label>Intervention Condition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control Condition</intervention_name>
    <description>Caregivers will access Nutrition and Health Promotion material. Care Recipients will access words and card games</description>
    <arm_group_label>Control Condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        CAREGIVER (CG)

        Inclusion Criteria:

          -  MMSE â‰¥ 26 (with Mungus age and education correction)

          -  Providing care for a friend or relative with AD for a minimum of eight hours per week
             for at least the past six months

          -  Being over the age of 21 years

          -  Living with or nearby the patient

          -  Having a telephone

          -  Planning to stay in the study geographic area for the duration of the study

        Exclusion Criteria:

          -  Not providing care to someone with memory problems

          -  Paid caregivers

          -  Has terminal illness with life expectancy of 6 months or less

        CARE RECIPIENT (CR)

        Inclusion Criteria:

          -  MMSE 18 - 25 (with Mungus age and education correction) (if scores high on MMSE, the
             care recipient has to score 1.0 in the Clinical Dementia Rating Scale (CDR))

          -  Needs help with higher level of IADL (e.g., managing finances, helping remember
             appointments, handling medications)

          -  Show memory problems

        Exclusion Criteria:

          -  Lives in nursing home or facility

          -  Going to be placed in a facility in the next 6 months

          -  Has terminal illness with life expectancy of 6 months or less
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara J. Czaja, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Caregiver</keyword>
  <keyword>Psycho-social intervention</keyword>
  <keyword>Cognitive training</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Early on-set Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

